Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

NVO’s underwhelming data readout also stands to benefit Amgen AMGN, which is developing its weight-loss candidate, MariTide, in a mid-stage study. Unlike CagriSema, which delivered 22.7% weight ...

06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...

Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...

The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...

Novo is employing a different strategy with cagrisema and now amycretin, which both target GLP-1 and the hormone amylin. Novo reported Phase 1 data for an oral form of amycretin about a year ago.

"The CagriSema [...] data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes [...]," the analysts wrote.